Cocrystal Pharma (COCP) Competitors

VBI Vaccines (NASDAQ:VBIV) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Does the media favor VBIV or COCP?

In the previous week, VBI Vaccines had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for VBI Vaccines and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.13 beat VBI Vaccines' score of 0.00 indicating that VBI Vaccines is being referred to more favorably in the media.

Company	Overall Sentiment
VBI Vaccines	Neutral
Cocrystal Pharma	Neutral

Do insiders and institutionals hold more shares of VBIV or COCP?

12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by company insiders. Comparatively, 25.1% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is VBIV or COCP more profitable?

Cocrystal Pharma has a net margin of 0.00% compared to Cocrystal Pharma's net margin of -1,403.15%. VBI Vaccines' return on equity of -59.62% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VBI Vaccines	-1,403.15%	-199.61%	-58.20%
Cocrystal Pharma	N/A	-59.62%	-54.62%

Which has stronger valuation and earnings, VBIV or COCP?

Cocrystal Pharma has lower revenue, but higher earnings than VBI Vaccines. Cocrystal Pharma is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VBI Vaccines	$8.68M	1.72	-$113.30M	-$11.68	-0.05
Cocrystal Pharma	N/A	N/A	-$17.98M	-$1.99	-0.75

Do analysts rate VBIV or COCP?

Cocrystal Pharma has a consensus target price of $10.00, indicating a potential upside of 572.72%. Given VBI Vaccines' higher possible upside, analysts clearly believe Cocrystal Pharma is more favorable than VBI Vaccines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VBI Vaccines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Cocrystal Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, VBIV or COCP?

VBI Vaccines has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Does the MarketBeat Community prefer VBIV or COCP?

VBI Vaccines received 479 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.00% of users gave Cocrystal Pharma an outperform vote while only 74.96% of users gave VBI Vaccines an outperform vote.

Company	Underperform	Outperform
VBI Vaccines	Outperform Votes 500 74.96%	Underperform Votes 167 25.04%
Cocrystal Pharma	Outperform Votes 21 75.00%	Underperform Votes 7 25.00%

Summary

Cocrystal Pharma beats VBI Vaccines on 9 of the 16 factors compared between the two stocks.